These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21406473)

  • 1. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?
    Kelly CM; Pritchard KI; Trudeau M; Andreopoulou E; Hess K; Pusztai L
    Ann Oncol; 2011 Nov; 22(11):2387-2393. PubMed ID: 21406473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas.
    Rodrigues MJ; Albiges-Sauvin L; Wassermann J; Cottu PH
    Ann Oncol; 2011 Nov; 22(11):2530. PubMed ID: 21700734
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
    Vaz-Luis I; Ottesen RA; Hughes ME; Mamet R; Burstein HJ; Edge SB; Gonzalez-Angulo AM; Moy B; Rugo HS; Theriault RL; Weeks JC; Winer EP; Lin NU
    J Clin Oncol; 2014 Jul; 32(20):2142-50. PubMed ID: 24888816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.
    Zhou Q; Yin W; Du Y; Lu J
    PLoS One; 2014; 9(1):e83646. PubMed ID: 24392090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.
    Ali S; Hendry J; Le D; Mondal PK; Sami A; Chalchal H; Haider K; Ahmed O; El-Gayed A; Wright P; Pauls M; Johnson K; Ahmed S
    Sci Rep; 2022 Jan; 12(1):1068. PubMed ID: 35058536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
    Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
    Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer.
    Araki K; Saji S; Gallas M; Pegram M; Sasaki Y
    Breast Cancer; 2012 Apr; 19(2):95-103. PubMed ID: 21863310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Small HER2-positive breast cancer: which prognosis and which adjuvant treatment?].
    Gonçalves A; Vassilakopoulou M; Spano JP
    Bull Cancer; 2013 Sep; 100(9):847-56. PubMed ID: 23899689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate.
    Petrelli F; Barni S
    Med Oncol; 2011 Jun; 28(2):401-8. PubMed ID: 20195801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?
    Lin H; Zheng H; Ge C; Wang Q; Tang W; Zhang X; Zhou S; Jin X; Xu X; Du J; Fu J
    Clin Breast Cancer; 2020 Dec; 20(6):503-510. PubMed ID: 32653474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study.
    Olszewski AJ; Migdady Y; Boolbol SK; Klein P; Boachie-Adjei K; Sakr BJ; Sikov W; Shao T
    Breast Cancer Res Treat; 2013 Feb; 138(1):215-23. PubMed ID: 23354365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers.
    Horio A; Fujita T; Hayashi H; Hattori M; Kondou N; Yamada M; Adachi E; Ushio A; Gondou N; Sueta A; Yatabe Y; Iwata H
    Int J Clin Oncol; 2012 Apr; 17(2):131-6. PubMed ID: 21681642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
    O'Sullivan CC; Bradbury I; Campbell C; Spielmann M; Perez EA; Joensuu H; Costantino JP; Delaloge S; Rastogi P; Zardavas D; Ballman KV; Holmes E; de Azambuja E; Piccart-Gebhart M; Zujewski JA; Gelber RD
    J Clin Oncol; 2015 Aug; 33(24):2600-8. PubMed ID: 26101239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers.
    Musolino A; Boggiani D; Sikokis A; Rimanti A; Pellegrino B; Vattiato R; Sgargi P; Falcini F; Caminiti C; Michiara M; Leonardi F
    Cancer Treat Rev; 2016 Feb; 43():1-7. PubMed ID: 26827687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.